logo
How to make sure you're getting the right supplement. 5 expert tips to help you choose

How to make sure you're getting the right supplement. 5 expert tips to help you choose

CNN7 hours ago
Editor's note: The podcast Chasing Life With Dr. Sanjay Gupta explores the medical science behind some of life's mysteries big and small. You can listen to episodes here.
(CNN) — Take a walk down the supplement aisle of any local drugstore, and you will be confronted with a floor-to-ceiling wall of choices. Not just the usual suspects — vitamins and minerals — but also items as varied as turmeric, fish oil, probiotics and melatonin — as well as combinations that purport to burn fat (not muscle!), cure erectile dysfunction and boost memory. The deluge of options doesn't stop there. Endless social media posts claim a life-changing supplement or regimen will help you eliminate 'cortisol belly,' protect against the flu or 'reset' your hormones.
But exactly how many things do we humans need to buy in the race to optimize our health and live our best life? All this noise around supplements generates confusion and anxiety, obscuring what science there is and making it hard to separate fact from wishful thinking.
In the most basic sense, these products are meant to supplement the food in your diet with extra added 'dietary ingredients.' You would not be faulted for thinking that the US Food and Drug Administration regulates supplements — and the agency does, but probably not in the way you might think.
Thanks to a 1994 law called the Dietary Supplement Health and Education Act, or DSHEA, supplements are regulated more like a subcategory of foods, not a subcategory of medicine. This essentially means that the FDA does not have the authority to approve dietary supplements before they are marketed, unlike pharmaceuticals, which must be shown to be both safe and effective in clinical trials.
'DSHEA is the current framework that all dietary supplements are sold in,' supplement safety advocate Dr. Pieter Cohen told CNN Chief Medical Correspondent Dr. Sanjay Gupta recently on his podcast, Chasing Life.
The law, in part, allowed the industry to explode from approximately 4,000 products in 1994, to some 90,000 in 2017, according to estimates in a 2022 AMA Journal of Ethics policy paper.
'Now, that law in 1994 was initially … designed to better regulate vitamins and minerals,' explained Cohen, an associate professor of medicine at Harvard Medical School and an internist at Cambridge Health Alliance, where he leads the Supplement Research Program. 'What unfortunately happened — unfortunately, in my opinion — was that that same structure was expanded to include … all nature of botanicals; many different types of extracts, like, let's say, a cow thyroid extract; live microorganisms, like both bacteria and yeast, that are sold as probiotics; protein powders; amino acids. All this was lumped together under that same framework … and all of them were called 'dietary supplements' or 'dietary ingredients.''
You can listen to the full episode here.
The FDA does have some power to take action against supplements that are adulterated or misbranded, but only after they are on the market. 'The FDA is in the position of looking for problems out in the marketplace after supplements are being sold, and then working to try to identify the products, which is incredibly difficult, because they don't have an effective system to detect harms, and then to try to remove those dangerous products,' Cohen said.
While regulations exist, 'it's companies selling us whatever they choose to declare and identify as a dietary supplement,' he said. He called it 'a system that emphasizes access and minimizes the assurances of safety or at least leaves safety in the manufacturer's court.'
What should consumers do before plunking down money at the health food store? Cohen explains what you should know about product claims and offers five tips when deciding which supplements to buy, keep or toss.
How the FDA can and can't regulate the supplement industry doesn't even address the issue of what actually works and what you might actually need.
Some studies show certain well-known vitamins or minerals can help particular conditions, but often recommendations change after new information comes to light. Good-quality clinical trials are expensive and hard to conduct (or data are gathered through epidemiological studies, so cause and effect can't be definitively proven); they rarely are done on less-well known (or blended) supplements.
The label required on US supplements, in essence, occupies a gray zone, and the average consumer might not know that they are expected to read between the lines.
A product label is permitted to contain a claim about the effect of the supplement on the body's structure or function (for example, 'helps support flexibility'). But the label 'may not claim to diagnose, mitigate, treat, cure, or prevent a specific disease or class of diseases,' according to DSHEA.
The law allows manufacturers to make those gray-zone, health-adjacent claims as long as they include a disclaimer that the claim has not been evaluated by the FDA.
The situation is not likely to change any time soon.
'A core concern I have with the current regulatory framework that really inhibits us moving forward is that there is no incentive for manufacturers to conduct carefully done clinical trials,' Cohen said.
'One thing we haven't talked about yet is that one other part of the law is that supplements can claim to have health effects without it being proven in humans,' he noted. 'Since you can do that without doing a clinical trial, what's the incentive to invest in all that money, millions of dollars, to do a clinical trial?
'The only potential outcome is negative — because if you're right, you were already advertising it as it was beneficial to your health and all you did was to prove that your claim is correct,' he said. 'But more likely, if it turns out it doesn't really work like you had hoped it did, and all that money is wasted, and then you've got a problem. But the good news, I guess, is that you can still keep on selling it as if it does work, even when the studies come out negative.'
The FDA has certain best practice rules in place when it comes to manufacturing, but it lacks oversight to ensure what is on the label is actually in the supplement, according to Cohen. That's why it's essential to choose supplements with a discerning eye.
'Toss away all supplements that do not include the official stamps from NSF (NSF International) or USP (US Pharmacopeia),' said Cohen said via email, referring to two independent, not-for-profit agencies that test supplements and then certify them.
'The FDA does not test supplements before they are sold,' he said. 'Unless supplements have been certified by a high-quality third-party organization, such as NSF or USP, it is not possible to know what's really inside the bottle.'
'Both those groups do deep dives into the quality of manufacturing,' Cohen told Gupta on the podcast. 'They look at the original ingredients that are coming (so that) when consumers are going in to purchase this online or in a store, that the label accurately represents what's in the product.'
Another reputable third-party tester is ConsumerLab.com.
But remember, none of these organizations test for efficacy, that is whether a supplement does what it claims to do.
'If you say something's good for gut health or will boost your immunity, those claims are not assessed by these companies,' Cohen told Gupta. 'The companies are just looking at — is the powder in the bottle the same as what's on the label?'
A good rule of thumb when checking ingredient lists for supplements is less is more.
'Toss away all supplements that list two or more botanical ingredients on the label,' Cohen said.
'Manufacturers are not required to share the details of each ingredient when mixing multiple botanical ingredients in the same supplement,' he said. For example, you might not know the ratio of one ingredient to the others, how fresh each one is, or the process by which each is prepared and then blended together.
'The only way to ensure that sufficient information about the botanical is provided on the label, (is to) select only single-ingredient supplements,' he added.
When you shop for dietary supplements, avoid products that claim in vague language to promote health benefits, Cohen said, such as 'boosts immunity' or 'improves cognition.'
'Supplement claims are not vetted by the FDA, and manufacturers do not need to perform studies of the supplement to demonstrate any benefit before selling the product,' he noted.
Cohen said it's best to avoid supplements with these types of claims and instead 'obtain information about benefits and risks of supplements from a reliable, independent source, such as the National Institutes of Health's Office of Dietary Supplements.'
Supplements can lose potency or, like fish oil, even go bad.
'Toss away all supplements that are past their expiration date,' Cohen said.
'Supplements past their expiration date are unlikely to have the correct amount of active ingredients as listed on the label,' he explained.
It's important to incorporate any supplements prescribed by your doctor in your routine on a consistent basis. Following your annual wellness visit, your physician might say, for example, that you need more iron or vitamin B12 or vitamin D based on bloodwork.
'Take all the supplements that your doctor recommends,' Cohen said.
'Many vitamin and mineral supplements are key to treating a variety of health conditions, so if your doctor recommends one or more supplements, remember to take them regularly,' he said.
Most healthy people probably don't need to take even a multivitamin, according to Cohen.
'My clinical experience is that regardless of how people are eating, as long as people are not on a highly restrictive diet, that they are going to get sufficient vitamins and minerals,' he told Gupta.
'Even if they're eating mainly manufactured or processed foods, or they're growing everything in their own garden, because of supplementation (in the food system), I'm not seeing serious vitamin deficiencies in my practice.'
Of course, it is not a bad idea to check with your doctor before you start a new supplement, and certainly let them know during your annual exam what you are currently taking. Some supplements can interact with certain medications, while others shouldn't be used by people with certain health conditions.
We hope these five tips help you make better sense of supplements. Listen to the full episode here. Join us next week for a new episode of the Chasing Life podcast.
CNN Podcasts' Madeleine Thompson and Kyra Dahring contributed to this report.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis

Yahoo

time14 minutes ago

  • Yahoo

Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis

SOUTH SAN FRANCISCO, Calif., July 15, 2025--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Division of Hepatology and Nutrition of the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the completed PORTOLA Phase 2a clinical trial evaluating zetomipzomib, a first-in-class selective immunoproteasome inhibitor, in patients with autoimmune hepatitis (AIH). "We are pleased that the FDA has lifted the partial clinical hold on zetomipzomib in AIH after their review of our comprehensive safety assessment of the zetomipzomib program," said Chris Kirk, PhD, CEO and co-founder of Kezar. "We continue to believe that zetomipzomib has the potential to positively transform the lives of patients living with AIH. We look forward to engaging with the FDA to align on the design of the next clinical trial of zetomipzomib in AIH." Although Kezar has suspended development of zetomipzomib in lupus nephritis (LN) to focus on AIH, the company met with the Independent Data Monitoring Committee (IDMC) for the previously terminated PALIZADE clinical trial to review the safety profile of zetomipzomib. The IDMC has provided Kezar with recommendations for conducting future clinical trials in LN. Based on this feedback and internal analysis of safety data across all clinical studies involving zetomipzomib, Kezar plans to respond to the FDA Division of Rheumatology and Transplant Medicine with a request to lift the clinical hold on zetomipzomib in LN. About Zetomipzomib Zetomipzomib is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases. Preclinical research demonstrates that selective immunoproteasome inhibition results in a broad anti-inflammatory response in animal models of several autoimmune diseases, while avoiding immunosuppression. Data generated from completed clinical trials provide evidence that zetomipzomib exhibits a favorable safety and tolerability profile for development in severe, chronic autoimmune diseases. About Autoimmune Hepatitis Autoimmune hepatitis (AIH) is a rare chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage, severely impacting patients' physical health and quality of life. Lifelong maintenance therapy is required to avoid relapse and burdensome adverse effects. If left untreated, AIH can lead to cirrhosis, liver failure and hepatocellular carcinoma. In the United States, AIH affects approximately 100,000 individuals, with incidence rates increasing. The cause of this condition remains unclear, with females affected four times as often as males. Currently, standard of care treatment for AIH is chronic, immunosuppressive treatment with corticosteroids that frequently cause life-altering side effects, including diabetes, osteoporotic fractures and cataracts. There is a significant need for treatment regimens that reduce or remove the need for chronic immunosuppression from use of corticosteroids. About Kezar Life Sciences Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases. Zetomipzomib, a selective immunoproteasome inhibitor, is currently being evaluated for autoimmune hepatitis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. For more information, visit and follow us on LinkedIn, Facebook, Twitter and Instagram. Cautionary Note on Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "can," "should," "expect," "believe," "potential," "anticipate" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Kezar's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Kezar's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the timing and outcome of regulatory submissions and interactions with the FDA, EMA or any other regulatory agencies with respect to zetomipzomib or Kezar's clinical trials, the initiation of an additional clinical trial of zetomipzomib in AIH, and expectations regarding the removal of the clinical hold of zetomipzomib in LN, and the likelihood of obtaining regulatory approval of zetomipzomib. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, difficulties enrolling and conducting our clinical trials, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Kezar's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" contained therein. Except as required by law, Kezar assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. View source version on Contacts Investor and Media Contact:Gitanjali JainSenior Vice President, Investor Relations and External AffairsKezar Life Sciences, Melden Sie sich an, um Ihr Portfolio aufzurufen.

US appeals court upholds West Virginia restriction on abortion pill sales
US appeals court upholds West Virginia restriction on abortion pill sales

Hamilton Spectator

time23 minutes ago

  • Hamilton Spectator

US appeals court upholds West Virginia restriction on abortion pill sales

CHARLESTON, (AP) — A federal appeals court on Tuesday upheld a lower court's decision to restrict abortion pill sales in West Virginia. A three-judge panel of the 4th U.S. Circuit Court of Appeals in Richmond, Virginia, affirmed a ruling by a U.S. district judge in 2023 despite federal regulators' approval of the abortion pill as a safe and effective medication. Most Republican-controlled states have enacted or adopted abortion bans of some kind, including restricting abortion pills by default, since the U.S. Supreme Court in 2022 overturned Roe v. Wade , the 1973 ruling that provided nationwide access to abortion. All have been challenged in court. The Supreme Court ruled in the case of Dobbs v. Jackson Women's Health Organization. U.S. District Court Judge Robert C. Chambers had ruled that the near-total abortion ban signed by then-Republican Gov. Jim Justice in September 2022 took precedence over approvals from the U.S. Food and Drug Administration. 'For us to once again federalize the issue of abortion without a clear directive from Congress, right on the heels of Dobbs, would leave us one small step short of defiance,' 4th Circuit Judge J. Harvie Wilkinson III wrote for the court. 'One can of course agree or disagree with the Dobbs decision. But that is not the point,' Wilkinson said. 'At a time when the rule of law is under blunt assault, disregarding the Supreme Court is not an option.' West Virginia Gov. Patrick Morrisey, who took office in January, had defended challenges to the abortion law when he served as attorney general. 'Big win out of the 4th Circuit today,' Morrisey said in a statement. GenBioPro Inc., the country's only manufacturer of a generic version of the abortion pill mifepristone, had argued that the state cannot block access to a FDA-approved drug. Chambers had dismissed the majority of GenBioPro's challenges, finding there is 'no disputing that health, medicine, and medical licensure are traditional areas of state authority.' Appeals judge DeAndrea Gist Benjamin concurred and dissented in part Tuesday, calling it a 'troubling opinion.' 'Put plainly, this law erects barriers to life-saving healthcare for countless West Virginians in ways not envisioned by Congress,' Benjamin wrote. Not at issue in the appeal was a challenge by GenBioPro concerning a separate West Virginia law that stopped providers from prescribing mifepristone by telehealth. Chambers had allowed that challenge to proceed. The U.S. Supreme Court last year unanimously preserved access to mifepristone , which is used in nearly two-thirds of all abortions in the U.S. in 2023.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store